DK0871476T3 - Tørret blodfaktorpræparat indeholdende trehalose - Google Patents

Tørret blodfaktorpræparat indeholdende trehalose

Info

Publication number: DK0871476T3
Authority: DK; Denmark
Prior art keywords: blood factor; preparation containing; dried blood; containing trehalose; factor preparation
Prior art date: 1995-01-19

Application number

DK96900633T

Other languages

Danish (da)

English (en)

Inventor

Bruce Joseph Roser

Original Assignee

Elan Drug Delivery Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1995-01-19

Filing date

1996-01-19

Publication date

2003-11-10

1996-01-19 Application filed by Elan Drug Delivery Ltd filed Critical Elan Drug Delivery Ltd

2003-11-10 Application granted granted Critical

2003-11-10 Publication of DK0871476T3 publication Critical patent/DK0871476T3/da

Links

HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 title abstract 2
HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 title abstract 2
HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 title abstract 2
229960000182 blood factors Drugs 0.000 title abstract 2
102000008100 Human Serum Albumin Human genes 0.000 abstract 1
108091006905 Human Serum Albumin Proteins 0.000 abstract 1
239000000203 mixture Substances 0.000 abstract 1
230000003019 stabilising effect Effects 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/36—Blood coagulation or fibrinolysis factors
- A61K38/37—Factors VIII
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/482—Serine endopeptidases (3.4.21)
- A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Oil, Petroleum & Natural Gas (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Hematology (AREA)
Immunology (AREA)
Zoology (AREA)
Gastroenterology & Hepatology (AREA)
Biochemistry (AREA)
Molecular Biology (AREA)
Organic Chemistry (AREA)
Dermatology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Diabetes (AREA)
Biomedical Technology (AREA)
Biotechnology (AREA)
Cell Biology (AREA)
Developmental Biology & Embryology (AREA)
Virology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicinal Preparation (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

DK96900633T 1995-01-19 1996-01-19 Tørret blodfaktorpræparat indeholdende trehalose DK0871476T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GBGB9501040.1A GB9501040D0 (en)	1995-01-19	1995-01-19	Dried composition
PCT/GB1996/000119 WO1996022107A1 (fr)	1995-01-19	1996-01-19	Composition de facteur sanguin deshydrate comprenant du trehalose

Publications (1)

Publication Number	Publication Date
DK0871476T3 true DK0871476T3 (da)	2003-11-10

Family

ID=10768253

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
DK96900633T DK0871476T3 (da)	1995-01-19	1996-01-19	Tørret blodfaktorpræparat indeholdende trehalose
DK03002147T DK1308170T3 (da)	1995-01-19	1996-01-19	Törret blodfaktorpræparat indeholdende trehalose

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
DK03002147T DK1308170T3 (da)	1995-01-19	1996-01-19	Törret blodfaktorpræparat indeholdende trehalose

Country Status (15)

Country	Link
US (2)	US6649386B2 (fr)
EP (4)	EP2258402A3 (fr)
JP (1)	JP3898221B2 (fr)
KR (1)	KR100417593B1 (fr)
CN (1)	CN1152713C (fr)
AT (2)	ATE413885T1 (fr)
AU (1)	AU704317B2 (fr)
CA (2)	CA2671383C (fr)
DE (2)	DE69637749D1 (fr)
DK (2)	DK0871476T3 (fr)
ES (2)	ES2316658T3 (fr)
GB (1)	GB9501040D0 (fr)
PT (2)	PT1308170E (fr)
SI (1)	SI1308170T1 (fr)
WO (1)	WO1996022107A1 (fr)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7244824B2 (en) *	1995-01-19	2007-07-17	Quadrant Drug Delivery Limited	Dried blood factor composition comprising trehalose
US7253262B2 (en) *	1995-01-19	2007-08-07	Quandrant Drug Delivery Limited	Dried blood factor composition comprising trehalose
GB9501040D0 (en) *	1995-01-19	1995-03-08	Quadrant Holdings Cambridge	Dried composition
US6964771B1 (en)	1995-06-07	2005-11-15	Elan Drug Delivery Limited	Method for stably incorporating substances within dry, foamed glass matrices
US6632648B1 (en) *	1996-05-14	2003-10-14	Elan Drug Delivery Limited	Methods of terminal sterilization of fibrinogen
GB9616536D0 (en) *	1996-08-06	1996-09-25	Quadrant Holdings Cambridge	Co-amoxiclav dosage form
AUPO871997A0 (en) *	1997-08-25	1997-09-18	Csl Limited	Dried biologically or therapeutically active preparations
DK1820516T3 (da)	1999-02-22	2013-10-28	Univ Connecticut	Nye albuminfrie faktor VIII-præparater
BR0211842A (pt) *	2001-08-10	2004-08-31	Hayashibara Biochem Lab	Associado, processos para produzir um associado de trealose ou maltitol e um ou mais compostos de ìon metálico, um produto em pó e um alimento marinho seco, método para formar um associado de trealose ou maltitol e um ou mais compostos de ìon metálico, composição, produto em pó, agente e tempero para alimentos
CA2538794C (fr)	2003-09-12	2016-04-19	Antigenics, Inc.	Vaccin pour le traitement et la prevention de l'infection provoquee par le virus de l'herpes simplex
EP1755652B1 (fr) *	2004-03-19	2010-11-24	Baxter International Inc.	Facteur ixa pour le traitement de troubles de saignement
DE602005016402D1 (de)	2004-05-24	2009-10-15	Genvault Corp	Stabile lagerung von protein und stabile lagerung von nukleinsäure in wiedergewinnbarer form
KR100624013B1 (ko)	2004-06-25	2006-09-19	주식회사 녹십자홀딩스	동결건조된 알부민 비함유 재조합 사람 혈액응고 제 8인자 제제
US8133484B2 (en)	2006-12-15	2012-03-13	Lifebond Ltd	Hemostatic materials and dressing
JP2010513462A (ja) *	2006-12-20	2010-04-30	バイエル・ヘルスケア・エルエルシー	第ＶＩＩおよび第ＶＩＩａ因子組成物
EP1958618A1 (fr)	2007-02-15	2008-08-20	Octapharma AG	Procédé destiné à la lyophilisation par reconstitution optimisée de biopolymères
BRPI0821591A2 (pt) *	2007-12-21	2016-05-03	Inspiration Biopharmaceuticals Inc	composição liofilizada e métodos de preparação de composição seca estável do fator ix e de liofilização de formulação farmacêutica
SG187410A1 (en)	2007-12-28	2013-02-28	Baxter Int	Recombinant vwf formulations
US11197916B2 (en)	2007-12-28	2021-12-14	Takeda Pharmaceutical Company Limited	Lyophilized recombinant VWF formulations
WO2010031007A2 (fr)	2008-09-12	2010-03-18	Genvault Corporation	Matrices et support pour le stockage et la stabilisation de biomolécules
EP2349314B1 (fr)	2008-10-21	2013-02-27	Baxter International Inc.	Formulations de vwf recombinant lyophilisé
MX339060B (es)	2008-11-07	2016-05-09	Baxter Int	Formulaciones del factor viii.
WO2011077388A1 (fr)	2009-12-22	2011-06-30	Lifebond Ltd	Modification d'agents de réticulation enzymatiques pour la maîtrise des propriétés des matrices réticulées
EP2732262A4 (fr) *	2011-07-13	2014-12-10	Denator Ab	Procédé de stabilisation d'échantillons biologiques fluides
CN102416171B (zh) *	2011-12-06	2013-12-25	中国医学科学院输血研究所	高纯度凝血酶原复合物制品干热病毒灭活过程中的保护剂
US9700486B2 (en)	2013-04-24	2017-07-11	Corning Incorporated	Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
AU2014368594B2 (en) *	2013-12-19	2020-03-05	Janssen Vaccines & Prevention B.V.	Improved formulations for virosomes
CN106687126B (zh)	2014-08-04	2020-07-28	杰特有限公司	因子viii制剂
EA201792501A1 (ru)	2015-05-13	2018-10-31	Эйдженус Инк.	Вакцины для лечения и профилактики рака
CN107333750A (zh) *	2017-06-11	2017-11-10	成都吱吖科技有限公司	一种长时血液细胞稳定剂
MA52363A (fr)	2018-04-26	2021-03-03	Agenus Inc	Compositions peptidiques de liaison à une protéine de choc thermique (hsp) et leurs méthodes d'utilisation
US11998654B2 (en)	2018-07-12	2024-06-04	Bard Shannon Limited	Securing implants and medical devices
WO2021001522A1 (fr)	2019-07-04	2021-01-07	CSL Behring Lengnau AG	Facteur de von willebrand (vwf) tronqué pour augmenter la stabilité in vitro du facteur viii de coagulation
JP2025512143A (ja)	2020-11-09	2025-04-17	武田薬品工業株式会社	酸化ケイ素吸着を使用する血漿からのｆｖｉｉｉの精製
WO2022261716A1 (fr) *	2021-06-16	2022-12-22	Exopharm Limited	Formulations aqueuses pour la conservation de vésicules extracellulaires
WO2024102796A2 (fr) *	2022-11-08	2024-05-16	University Of Wyoming	Stabilisation de substances biologiques et du facteur viii de coagulation sanguine humain à l'état sec

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4361509A (en)	1981-12-14	1982-11-30	Scripps Clinic And Research Foundation	Ultrapurification of factor VIII using monoclonal antibodies
US4495175A (en) *	1982-08-05	1985-01-22	University Of Rochester	Preparation of highly purified human antihemophilic factor
FI86885C (fi)	1984-04-20	1992-10-26	Genentech Inc	Foerfarande foer framstaellning av human rekombinantfaktor viii och nukleinsyrasekvenser och vektorer anvaend daertill
EP0182448A3 (fr)	1984-08-24	1987-10-28	Genetics Institute, Inc.	Production de facteur VIII et produits apparentés
JPH0779694B2 (ja) *	1985-07-09	1995-08-30	カドラントバイオリソ−シズリミテツド	蛋白質および同類品の保護
US4758657A (en) *	1985-07-11	1988-07-19	Armour Pharmaceutical Company	Method of purifying Factor VIII:C
US4806343A (en) *	1986-03-13	1989-02-21	University Of Southwestern Louisiana	Cryogenic protectant for proteins
CA1329760C (fr) *	1987-10-29	1994-05-24	Ted C. K. Lee	Formulation de plasma et de proteines recombinantes dans des milieux a grande force ionique
US4877608A (en) *	1987-11-09	1989-10-31	Rorer Pharmaceutical Corporation	Pharmaceutical plasma protein formulations in low ionic strength media
CA2051092C (fr) *	1990-09-12	2002-07-23	Stephen A. Livesey	Methode et appareillage pour la cryopreservation, la stabilisation a sec et la rehydratation de suspensions biologiques
DE4111393A1 (de) *	1991-04-09	1992-10-15	Behringwerke Ag	Stabilisierte faktor viii-praeparationen
US5288853A (en) *	1992-04-30	1994-02-22	Alpha Therapeutic Corporation	Factor viii purification process
CA2124690C (fr) *	1992-10-02	2007-09-11	Thomas Osterberg	Composition contenant une preparation du facteur de coagulation viii, methode de preparation et utilisation d'un surfactant comme stabilisateur
SE504074C2 (sv)	1993-07-05	1996-11-04	Pharmacia Ab	Proteinberedning för subkutan, intramuskulär eller intradermal administrering
WO1995003332A1 (fr) *	1993-07-23	1995-02-02	Baxter International Inc.	Facteur viii humain active et procede de preparation
US5576291A (en) *	1993-09-13	1996-11-19	Baxter International Inc.	Activated factor VIII as a therapeutic agent and method of treating factor VIII deficiency
US5955448A (en) *	1994-08-19	1999-09-21	Quadrant Holdings Cambridge Limited	Method for stabilization of biological substances during drying and subsequent storage and compositions thereof
US7253262B2 (en) *	1995-01-19	2007-08-07	Quandrant Drug Delivery Limited	Dried blood factor composition comprising trehalose
GB9501040D0 (en) *	1995-01-19	1995-03-08	Quadrant Holdings Cambridge	Dried composition
US5804420A (en) *	1997-04-18	1998-09-08	Bayer Corporation	Preparation of recombinant Factor VIII in a protein free medium
DK1820516T3 (da) *	1999-02-22	2013-10-28	Univ Connecticut	Nye albuminfrie faktor VIII-præparater

1995
- 1995-01-19 GB GBGB9501040.1A patent/GB9501040D0/en active Pending
1996
- 1996-01-19 PT PT03002147T patent/PT1308170E/pt unknown
- 1996-01-19 DE DE69637749T patent/DE69637749D1/de not_active Expired - Lifetime
- 1996-01-19 WO PCT/GB1996/000119 patent/WO1996022107A1/fr not_active Ceased
- 1996-01-19 CA CA2671383A patent/CA2671383C/fr not_active Expired - Lifetime
- 1996-01-19 SI SI9630765T patent/SI1308170T1/sl unknown
- 1996-01-19 AT AT03002147T patent/ATE413885T1/de active
- 1996-01-19 EP EP10008828A patent/EP2258402A3/fr not_active Withdrawn
- 1996-01-19 CA CA002210872A patent/CA2210872C/fr not_active Expired - Lifetime
- 1996-01-19 JP JP52213396A patent/JP3898221B2/ja not_active Expired - Fee Related
- 1996-01-19 PT PT96900633T patent/PT871476E/pt unknown
- 1996-01-19 EP EP96900633A patent/EP0871476B1/fr not_active Expired - Lifetime
- 1996-01-19 EP EP03002147A patent/EP1308170B1/fr not_active Expired - Lifetime
- 1996-01-19 EP EP08010169A patent/EP1974741A1/fr not_active Withdrawn
- 1996-01-19 DK DK96900633T patent/DK0871476T3/da active
- 1996-01-19 AU AU44540/96A patent/AU704317B2/en not_active Expired
- 1996-01-19 KR KR1019970704891A patent/KR100417593B1/ko not_active Expired - Lifetime
- 1996-01-19 CN CNB961926600A patent/CN1152713C/zh not_active Expired - Lifetime
- 1996-01-19 DK DK03002147T patent/DK1308170T3/da active
- 1996-01-19 DE DE69629209T patent/DE69629209T2/de not_active Expired - Lifetime
- 1996-01-19 ES ES03002147T patent/ES2316658T3/es not_active Expired - Lifetime
- 1996-01-19 US US08/875,796 patent/US6649386B2/en not_active Expired - Lifetime
- 1996-01-19 ES ES96900633T patent/ES2202425T3/es not_active Expired - Lifetime
- 1996-01-19 AT AT96900633T patent/ATE245442T1/de active
2009
- 2009-02-13 US US12/371,459 patent/US7803911B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
EP1308170A2 (fr)	2003-05-07
US6649386B2 (en)	2003-11-18
CA2671383A1 (fr)	1996-07-25
DK1308170T3 (da)	2008-12-15
WO1996022107A1 (fr)	1996-07-25
EP0871476B1 (fr)	2003-07-23
CN1179107A (zh)	1998-04-15
ES2202425T3 (es)	2004-04-01
EP1974741A1 (fr)	2008-10-01
SI1308170T1 (sl)	2009-04-30
US20020128207A1 (en)	2002-09-12
ATE245442T1 (de)	2003-08-15
PT1308170E (pt)	2008-12-26
JP3898221B2 (ja)	2007-03-28
KR19980701500A (ko)	1998-05-15
EP1308170B1 (fr)	2008-11-12
DE69629209T2 (de)	2004-02-19
ATE413885T1 (de)	2008-11-15
EP0871476A1 (fr)	1998-10-21
EP2258402A3 (fr)	2011-01-05
AU4454096A (en)	1996-08-07
JPH11503719A (ja)	1999-03-30
PT871476E (pt)	2003-12-31
CA2210872C (fr)	2009-09-08
EP1308170A3 (fr)	2004-03-03
CN1152713C (zh)	2004-06-09
ES2316658T3 (es)	2009-04-16
CA2671383C (fr)	2012-04-24
GB9501040D0 (en)	1995-03-08
US7803911B2 (en)	2010-09-28
AU704317B2 (en)	1999-04-22
DE69637749D1 (de)	2008-12-24
DE69629209D1 (de)	2003-08-28
KR100417593B1 (ko)	2004-04-30
EP2258402A2 (fr)	2010-12-08
CA2210872A1 (fr)	1996-07-25
US20090149388A1 (en)	2009-06-11

Publication	Publication Date	Title
DK0871476T3 (da)	2003-11-10	Tørret blodfaktorpræparat indeholdende trehalose
MX9304710A (es)	1994-05-31	Composicion farmaceutica y/o cosmetica y su uso.
IT1276723B1 (it)	1997-11-03	Formulazioni di analoghi dell'insulina
NO179911C (no)	1997-01-08	Optisk aktivt 5H-pyrrolo[3,4-bÅpyrazinderivat samt farmasöytiske preparater inneholdende derivatet
ES2096727T5 (es)	2001-07-01	Productos cosmeticos y farmaceuticos que contienen extensinas.
DE3675996D1 (de)	1991-01-17	Mittel mit kontinuierlicher peptidfreisetzung.
ATE129146T1 (de)	1995-11-15	Stiftzusammensetzung enthaltend salzsäurenatrium und stearylalkohol.
DE59101404D1 (de)	1994-05-26	Topische Präparate.
DE59107240D1 (de)	1996-02-22	Emulgatorfreie Emulsionspolymere in pharmazeutischen Zubereitungen mit verzögerter Wirkstofffreigabe und ihre Herstellung
ITMI931371A0 (it)	1993-06-25	Procedimento per la preparazione dell'erdosteina
KR900700471A (ko)	1990-08-13	신규의 2,3-티오모르폴린디온-2-옥심유도체, 이들을 함유하는 약제학적 조성물 및 제법
DE3869232D1 (de)	1992-04-23	Abkoemmlinge von bornan-3-spiro-l'-cyclopentan und diese enthaltende riechstoffzusammensetzungen.
IT1215261B (it)	1990-01-31	Composizioni farmaceutiche adattivita' antigalattopoietica.
KR950026459U (ko)	1995-10-16	착탈식 신발주머니를 가진 어린이용 책가방
KR900016452U (ko)	1990-10-05	성냥갑의 적린 도포장치
FR2608597B1 (fr)	1989-05-12	Compositions pharmaceutiques contenant de l'acetylsalicylate de lysine
ES1021366Y (es)	1993-04-16	Calzado infantil
MX9203261A (es)	1992-07-01	Nuevas 12-amino-piridazino [4',5':3,4] pirrolo[2,1-a]-isoquinolinas y composiciones farmaceuticas que las contienen.
IT1219429B (it)	1990-05-18	Composizioni farmaceutiche ad attivita' antiprolattinica
KR910010588U (ko)	1991-07-29	아동용 신발
RO91512A2 (fr)	1987-04-30	Composition medicamenteuse d'usage dermatologique
ITAN940061A0 (it)	1994-12-01	Calzatura di peso limitato e di elevate capacita' traspiranti
ES1012015Y (es)	1991-01-01	Calzado infantil perfeccionado.
ITMI921253A1 (it)	1993-11-22	Composizione farmaceutica avente attivita' antivirale
ITMI921252A0 (it)	1992-05-22	Composizione farmaceutica ad attivita' antitosse